S4. Optimization of anti-HMW CAR intracellular domain. Three variations of the anti-HMW CAR extracellular domain were evaluated to determine the optimal format, based on transduction efficiency and cytokine release. Constructs differed in their T cell signaling motifs (28z = CD28 transmembrane / signaling domain and CD3^c signaling domain; 28BBz = CD28 transmembrane / signaling domain, 4-1BB signaling domain and CD3^c signaling domain; CD8.28BBz = CD8 transmembrane domain, CD28 signaling domain, 4-1BB signaling domain and CD3^c signaling domain); all contained the L2H (VL-218-VH) extracellular domain. Values in **bold-face type** are the greatest for that parameter with that donor or the mean of all donors.

	28z		28BBz		CD8.28BBz	
	% Transduction ¹	IFN-γ release ²	% Transduction ¹	IFN-γ release ²	% Transduction ¹	IFN-γ release ²
Donor 1	48	10345	15	2405	12	9830
Donor 2	65	3385	18	2055	16	4355
Donor 3	46	27400	26	9735	15	31400
MEAN (SEM)	53 (6)	13710 (7134)	20 (3)	4732 (2504)	14 (1)	15195 (8255)

¹ Gene transfer efficiency in human PBL, as determined by flow cytometry on day 9 after transduction.

 2 IFN- γ concentration in the supernatant of an overnight coculture between anti-HMW CAR-transduced PBL and the HMW-expressing melanoma line 1300. Values are in pg/mL.